UBS Initiates Coverage On Adarx Pharmaceuticals with Buy Rating, Announces Price Target of $35

UBS analyst Michael Yee has initiated coverage on Adarx Pharmaceuticals (NASDAQ: ADRX) with a Buy rating. The firm has set a price target of $35 for the company's stock.